EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed/refractory large B-cell lymphoma: findings from a German monocentric study

Farina Eigendorff, Irina Filimonova, Sebastian Scholl, Anne Sayer-Klink, Silke Rummler, Christa Kunert, Klaus Pietschmann, Andrea Wittig, Andreas Hochhaus, Ulf Schnetzke

Journal of Cancer Research and Clinical Oncology · 01.05.2024 · 150 (5)

DOI: 10.1007/s00432-024-05765-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, online erschienen am 01.05.2024. Verfasst von Farina Eigendorff und 9 weiteren Autor:innen. Beteiligte Einrichtung: Klinik Für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Germany. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Jena.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Incorporating chimeric antigen receptor (CAR)-T cell therapy into relapsed or refractory large B-cell lymphoma (rr LBCL) treatment algorithms has yielded remarkable response rates and durable remissions, yet a substantial portion of patients experience progression or relapse. Variations in outcomes across treatment centers may be attributed to different bridging strategies and remission statuses preceding CAR-T cell therapy. Patients Twenty-nine consecutive adult patients receiving tisagenlecleucel (tisa-cel) for rr LBCL from December 2019 to February 2023 at Jena University Hospital were analyzed.

Results

The median age was 63, with a median of 3 prior treatments. Twenty patients (69%) were refractory to any systemic therapy before CAR-T cell treatment. Following leukapheresis, 25 patients (86%) received bridging therapy with the majority undergoing chemotherapy (52%) or combined modality therapy (32%). Radiotherapy (RT) was part of the bridging strategy in 44%, with moderately hypofractionated involved site RT (30.0 Gy/2.5 Gy) being applied most frequently (64%). Post-CAR-T infusion, the objective response rate at 30 days was 83%, with 55% achieving complete response. Twelve-month progression-free (PFS) and overall survival (OS) were 60% and 74%, respectively, with a median follow up of 11.1 months for PFS and 17.9 months for OS. Factors significantly associated with PFS were chemotherapy sensitivity pre-leukapheresis and response to bridging.

Conclusion

The study underscores the importance of minimal tumor burden at CAR-T initiation, emphasizing the need for suitable bridging regimens. The findings advocate for clinical trials and further real-world analyses to optimize CAR-T cell therapy outcomes by identifying the most effective bridging strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseHumansMaleMiddle AgedFemaleAgedAdultRemission InductionNeoplasm Recurrence, LocalGermanyReceptors, Antigen, T-CellRetrospective StudiesCombined Modality Therapy

Stichwörter der Autor:innen

BridgingCAR-TLarge B-cell lymphomaRadiotherapyTisagenlecleucel

Substanzen

tisagenlecleucelReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Klinik Für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Germany.
  • Comprehensive Cancer Center Central Germany (CCCG) Jena/Leipzig, Campus Jena, Jena, Germany.
  • Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Jena, Jena, Germany.
  • Institut für Transfusionsmedizin, Universitätsklinikum Jena, Jena, Germany.
  • Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Würzburg, Würzburg, Germany.
  • Klinik Für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Germany. ulf.schnetzke@med.uni-jena.de.

Förderung

  • Universitätsklinikum Jena

Zitieren

APA

Eigendorff, F., Filimonova, I., Scholl, S., Sayer-Klink, A., Rummler, S., Kunert, C., Pietschmann, K., Wittig, A., Hochhaus, A., & Schnetzke, U. (2024). Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed/refractory large B-cell lymphoma: findings from a German monocentric study. Journal of Cancer Research and Clinical Oncology, 150(5). https://doi.org/10.1007/s00432-024-05765-8

Vancouver

Eigendorff F, Filimonova I, Scholl S, Sayer-Klink A, Rummler S, Kunert C, et al. Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed/refractory large B-cell lymphoma: findings from a German monocentric study. Journal of Cancer Research and Clinical Oncology. 2024;150(5). doi:10.1007/s00432-024-05765-8

BibTeX
@article{Eigendorff2024,
  author = {Eigendorff, Farina and Filimonova, Irina and Scholl, Sebastian and Sayer-Klink, Anne and Rummler, Silke and Kunert, Christa and Pietschmann, Klaus and Wittig, Andrea and Hochhaus, Andreas and Schnetzke, Ulf},
  title = {Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed/refractory large B-cell lymphoma: findings from a German monocentric study},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  volume = {150},
  number = {5},
  doi = {10.1007/s00432-024-05765-8}
}
Kostenlos starten →